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Therapeutic Plasma Exchange in Pediatric Kidney 
Disease: 23-year Experience at the Severance Children’s 
Hospital in Korea
Purpose: The American Society for Apheresis provides clinical guidelines for the-
rapeutic apheresis in adults, but there are no guidelines for children. This study 
aimed to analyze the effect of therapeutic plasma exchange (TPE) in pediatric pa-
tients with various kidney diseases in Korea. 
Methods: We retrospectively reviewed the data of 16 children (up to 18 years of 
age) who were admitted to Severance Children’s Hospital with refractory kidney 
disease. All patients received TPE between 1994 and 2016. Clinical and laboratory 
characteristics such as age, weight, sex, change in blood urea nitrogen (BUN), and 
creatinine level before and after TPE, and complications after TPE were analyzed. 
Results: The mean age and weight of the 16 patients at the time of TPE was 11.3± 
4.0 years and 34.6±17.5 kg, respectively. The BUN level was 35.4 mg/dL before TPE 
and significantly decreased to 21.5 mg/dL (P=0.025) at 1 week and 20.5 mg/dL (P= 
0.01) at 1 month after TPE. The creatinine level significantly decreased from 1.20 
mg/dL before TPE to 0.90 mg/dL (P=0.02) at 1 week after TPE. Four complications 
(hypovolemia, anemia, hypocalcemia, and thrombocytopenia) were reported, but 
were not fatal. 
Conclusion: Our findings suggest that TPE is an effective therapeutic modality in 
children with refractory kidney disease and can be indicated for the treatment of 
various kidney diseases.
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Introduction
Therapeutic plasma exchange (TPE) is a treatment modality to remove cir­
culating pathologic substances from the plasma and replace them with a sub­
stitution fluid (e.g., albumin or plasma)1,2). TPE has been applied in various dis­
eases such as neurological diseases (e.g., myasthenia gravis, Guillain­Barré 
syndrome), hematological disorders (e.g., thrombotic thrombocytopenic pur­
pura, hemolytic uremic syndrome), metabolic disorders (e.g., inborn errors 
of metabolism, homozygous familial hypercholesterolemia), and kidney dis­
eases (e.g., the renal transplant candidate, antibody mediated renal allograft 
rejection, recurrent focal segmental glomerulosclerosis (FSGS) after renal 
transplantation, antineutrophil cytoplasmic antibodies and antiglomerular 
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basement membrane antibody­associated rapidly progres­
sing glomerulonephritis, and atypical hemolytic uremic 
syndrome (aHUS))3). 
The first reported plasmapheresis was performed at Johns 
Hopkins University in 19144). Decades later, the first plasma 
exchange in a human was conducted in a patient with Wal­
denstrom’s macroglobulinemia in 19605). The TPE techni­
que was developed gradually and the clinical application 
of TPE has expanded remarkably. The American Society 
for Apheresis (ASFA) guideline provides the clinical indi­
cations for the evidence­based use of therapeutic apheresis 
in adult studies6). In addition, TPE is a widely recognized 
therapeutic option in pediatric patients as well as in adults. 
However, there is no guideline for children, especially those 
with kidney disease.
In a PubMed search, there were about 30 papers regar­
ding TPE in pediatric patients with kidney disease7­9). There 
were particularly few studies about TPE in children with 
kidney disease in Korea10). Therefore, further study of TPE 
in pediatric patients with kidney diseases is warranted. 
TPE is an important treatment modality for children 
with renal and other immune­mediated diseases3). For the 
continued development of TPE as an optimal treatment 
modality in pediatric patients, accurate data are required 
based on long­term experience. 
The purpose of this study was to review the data of pe­
diatric patients with kidney diseases treated with TPE at a 
single institution over the last 23 years in terms of etiologies, 
characteristics, complications, and clinical outcomes. 
Materials and methods 
1. Patients
We retrospectively reviewed the data of children (up to 
18 years of age) who underwent TPE between 1994 and 
2016 in Severance Children’s Hospital. We identified 37 
children admitted to Severance Children’s Hospital who 
had undergone TPE during the study period. Among 
them, there were 19 patients (51.3%) with kidney diseases, 
9 patients (24.3%) with neurologic diseases, and 7 patients 
(18.9%) with hepatic diseases. Three of the patients with 
kidney diseases were excluded due to missing data; thus, 
16 patients (2 male and 14 female) with kidney diseases 
were included in this study. 
2. Data collection 
The patients’ medical records were obtained from the 
nephrology department and data including patients’ de­
mographic and clinical characteristics (age, sex, body 
weight, indication for TPE, treatment, prognosis), main 
features of the TPE procedures (frequency of TPE, site of 
initial vascular access, type of replacement fluid, plasma 
volume), and complications were analyzed. Blood urea ni­
trogen (BUN), serum creatinine, C3, C4, proteinuria and 
serum albumin levels were measured before and after TPE, 
and the values were compared. 
3. TPE procedure
Effective volume was calculated as effective plasma vo­
lume (mL)=body weight×70 mL/kg×(1­hematocrit). TPE 
was performed every other day, and a total 1­1.5 volume of 
plasma was exchanged, depending on patients’ weight and 
hematocrit. The replacement fluids were albumin 4% and/
or fresh frozen plasma (FFP) according to the indication for 
TPE. A double­lumen hemodialysis central venous catheter 
was inserted through the jugular, subclavian, or femoral 
vein according to the patient’s vascular anatomy. TPE was 
performed using COBE Spectra (Thermo BCT Inc., Lake­
wood, CO, USA) by centrifugation.
4. Statistical analysis
Continuous variables are expressed as the mean±standard 
deviation or medians with ranges. Data were analyzed 
with a paired t­test. All statistical analyses were performed 
by using SPSS software (version 22.0, IBM Corporation, 
Armonk, NY, USA) and a P value less than 0.05 was con­
sidered statistically significant. 
Results
1. Demographic data
From April 1994 to February 2016 a total of 16 patients 
with kidney diseases who were younger than 18 years 
underwent TPE. The clinical characteristics of the patients 
are shown in Table 1. There were two male and 14 female 
patients. The mean age at onset was 11.3±4.0 years and the 
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body weight was 34.6±17.5 kg. 
2. Therapeutic effects of TPE 
In this study, three patients underwent more than one 
TPE session, resulting in a total of 19 TPE sessions. Some 
patients responded very well to the first TPE session, but 
subsequently needed another course of TPE for the same 
or a different indication.
In the present study, the etiologies for TPE were lupus 
nephritis (9 patients), FSGS (4 patients), Denys­Drash 
syndrome (1 patient), microscopic polyarteritis (1 patient), 
and aHUS (1 patient). The patients were divided into four 
groups depending on the reason for TPE: refractory (12 
patients), recurrent (2 patients), rejection (1 patient), and 
others (4 patients) (Table 1). The refractory group comprised 
patients who had no response to steroid, cyclophospha­
mide, methylprednisolone, azathioprine, and cyclosporine 
treatment. The recurrent group comprised patients who 
presented recurrence after kidney transplantation, and the 
rejection groups comprised patients who presented acute 
rejection after kidney transplantation. 
The comparison between laboratory values (BUN and 
serum creatinine) before and after TPE is shown in Table 
1. BUN level at 1 week significantly decreased from 35.4 
mg/dL to 21.5 mg/dL (P=0.025) and creatinine level signifi­
cantly decreased from 1.20 mg/dL to 0.90 mg/dL (P=0.02). 
BUN level at 1 month after TPE significantly decreased 
from 35.4 mg/dL to 20.5 mg/dL (P=0.01) (Table 4). 
Also, in order to investigate the TPE effect in patients 
with lupus nephritis, C3, C4 and proteinuria values before 
and after TPE are shown in Table 2. In addition, Anti­DNA 
Ab titer was investigated for TPE effect evaluation in lupus 
nephritis (Table 2). Among the children with lupus ne­
phritis, six patients were found to have increased anti­DNA 
Ab titer before TPE. In addition, anti­DNA Ab titer de­
creased in 3 patients (patient 2, 5, 9) after TPE, and there 
was no difference in 5 patients (patient 1, 3, 4, 6, 8) after TPE 
(Table 2). 
And serum albumin and proteinuria values before and 
after TPE are shown in Table 3 to reveal the TPE effect in 
Table 1. The Characteristics and Therapeutic Effects of Patients who Underwent TPE
Patient Diagnosis Sex Age (year)
Weight 




1 weeks f/u 
BUN/Cr 
(mg/dL)
1 month f/u 
BUN/Cr 
(mg/dL)
1 Lupus nephritis F 15 50.6 1994 P Refractory 14.5/0.5 15.1/0.8 11.0/0.6
2 Lupus nephritis F 12 34 1994 P; MP; CYC Refractory 17/0.5 17.7/0.6 11.5/0.7
3 Lupus nephritis F 15 59 1997 P; MP Refractory 13.5/0.6 8.2/0.8 6.0/0.4
4 Lupus nephritis F 14 54.5 1997 MP Refractory 7.3/0.7 10/0.6 8.0/0.8
5 Lupus nephritis M 12 35.5 1998 - TTP 37/1.1 32.3/1.1 11.7/0.7
6 Lupus nephritis F 14 52.5 2000 P; CsA; MP; CYC Refractory 35.4/2.1 21.5/1 28.5/0.9
7 Lupus nephritis F 8 NA 2001 MP Refractory 84/3.2 33/1.3 Expire
8 Lupus nephritis F 11 NA 2001 P; MP Refractory 28/0.8 9.3/1.3 21.8/0.7
9-1 Lupus nephritis F 13 48 2005 P; CYC Refractory 71.5/6 63.5/5.8 73/7.5
9-2 18 45.5 2011 KT Rejection 43/2.26 25.5/1.79 26.4/1.78
10-1 FSGS F 10 26 1997 P; CsA; KT Recur 49.5/1.2 30/0.9 36/0.8
10-2 12 35 1999 CsA; P Refractory 53.5/1.8 38/1.5 NA
11-1 FSGS F 3 13.5 2001 P; CsA; MP; CYC Refractory 14/0.3 46/0.5 21.5/0.4
11-2 14 33 2013 CYC; KT Recur 35.9/1.2 11.9/0.49 24.7/0.65
12 FSGS F 16 54 2008 P; CsA; MP Refractory 34.2/2.2 24.4/0.9 18.9/1.5
13 FSGS F 7 15 2012 P TTP 23/0.58 20.7/0.57 9.9/0.64
14 Denys-Drash syndrome M 4 15.4 2011 Anti-hypertensive drug; PD ABO-incompatible 76.7/9.33 88/6.92 20.5/0.66
15 ANCA-associated RPGN F 7 7 2001 MP; CYC Refractory 117/2.3 20.8/1.6 23/1.3
16 Atypical HUS F 10 10 2008 CRRT Atypical HUS 87.1/6.3 24.5/2.5 8.8/0.7
Abbreviations: ANCA, anti-neutrophil cytoplasmic antibodies; CRRT, continuous renal replacement therapy; CsA, cyclosporine; CYC, cyclophosphamide; FSGS, 
focal segmental glomerulosclerosis; HUS, hemolytic-uremic syndrome; KT, kidney transplantation; F, female; M, male; MP, methylprednisolone; NA, not 
available; P, oral steroid; PD, peritoneal dialysis; RPGN, rapidly progressive glomerulonephritis; TPE, therapeutic plasma exchange; TTP, thrombotic thrombo-
cytopenic purpura; BUN, blood urea nitrogen; Cr, serum creatinine.
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FSGS patients. In patients with lupus nephritis, C3 level and 
C4 level at 1 month after TPE increased from 34 mg/dL to 
51.1 mg/dL (P=0.082) and from 6.9 mg/dL to 9.5 mg/dL (P= 
0.18), respectively. However, these results were not statistic­
ally significant compared to those in BUN and creatinine 
(Table 5). In patients with FSGS, albumin at 1 month after 
TPE increased from 2.6 g/dL to 3.1 g/dL (P= 0.322), but was 
not statistically significant (Table 6).
Table 2. Therapeutic Effects of Lupus Nephritis Patients who Underwent TPE 
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1 month f/u 
Anti-DNA Ab 
titer
1 Lupus nephritis F 15 Refractory 3+ 1+ 42/8 74/13 1:160, + 1:160, +
2 Lupus nephritis F 12 Refractory - - 41/6 64/7 1:160, + 1:40, +
3 Lupus nephritis F 15 Refractory 3+ 2+ 37/4 38/5 1:40, + 1:40, +
4 Lupus nephritis F 14 Refractory - - 35/12 27/7 1:160, + 1:160, +
5 Lupus nephritis M 12 TTP 3+ 3+ 16/12 72/21.4 1:160, + -
6 Lupus nephritis F 14 Refractory 3+ 3+ 90/19 NA - -
7 Lupus nephritis F 8 Refractory NA NA NA NA - NA
8 Lupus nephritis F 11 Refractory 3+ 1+ 20/1.4 30/2.4 - -
9-1 Lupus nephritis F 13 Refractory 3+ - 47/4.6 53/11 1:40, + -
9-2 Lupus nephritis 18 Rejection - - 75/8.2 NA NA NA
C3 reference range (90-180 mg/dL), C4 reference range (10-40 mg/dL).
Abbreviations: F, female; M, male; NA, not available; TPE, therapeutic plasma exchange; TTP, thrombotic thrombocytopenic purpura. 
Table 3. Therapeutic Effects of FSGS Patients who Underwent TPE
Patient Diagnosis Sex Age(year) Reason for TPE
Pre-TPE Urine Protein 
(postive on stick)
One month f/u Urine
Protein (postive on stick)
Pre-TPE 
Albumin (g/dL)
1 month f/u 
Albumin (g/dL)
10-1 FSGS F 10 Recur 3+ 2+ 2.8 3.5
10-2 12 Refractory 2+ - 3.9 4.1
11-1 FSGS F  3 Refractory 3+ 3+ 1.6 2.8
11-2 14 Recur 3+ 3+ 1.8 2.7
12 FSGS F 16 Refractory 3+ 3+ 1.1 2.4
13 FSGS F  7 TTP - - 4.4 2.9
Abbreviations: F, female; FSGS, focal segmental glomerulosclerosis; NA, not available; TPE, therapeutic plasma exchange; TTP, thrombotic thrombocytopenic 
purpura. 
Table 4. Laboratory Findings before and after TPE (at 1 Week and 1 Month)
Before TPE After 1 week* P-value After 1 month† P-value
BUN (mg/dL) 35.4 (17-49.5) 21.5 (15.1-30.0) 0.02 20.5 (11.0-24.7) 0.01
Creatinine (mg/dL)   1.20 (0.65-2.28) 0.90 (0.60-1.60) 0.02 0.70 (0.65-0.90) 0.11
*1 week immediately after TPE .
†1 month immediately after TPE. 
Abbreviations: TPE, therapeutic plasma exchange; BUN, blood urea nitrogen.
Table 5. Laboratory Findings and Proteinuria before and after 
TPE in Lupus Nephritis Patients
Before TPE After 1 month* P-value
C3 (mg/dL) 34±11.6 51.1±19.7 0.082
C4 (mg/dL) 6.9±4.0 9.5±6.3 0.18
Proteinuria (postive on stick) 2+ 1+ 0.052
*1 month immediately after TPE.
Abbreviations: TPE, therapeutic plasma exchange;BUN, blood urea nitro-
gen; Cr, serum creatinine.
Table 6. Laboratory Findings and Proteinuria before and after 
TPE in FSGS Patients
Before TPE After 1 month* P-value
Albumin (g/dL) 2.6±1.3 3.1±0.6 0.322
Proteinuria (postive on stick) 2+ 2+ 0.203
*1 month immediately after TPE.
Abbreviations: FSGS, focal segmental glomerulosclerosis; TPE, therapeutic 
plasma exchange.
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3. Clinical outcomes
Among the 16 patients, 3 patients received kidney trans­
plantation and 3 patients were treated with hemodialysis 
due to end­stage renal disease (ESRD). A complete response 
was defined as a patient who was treated after TPE with no 
more following up. A partial response was defined as pa­
tients without proteinuria after TPE or other treatments 
and patients with well­controlled proteinuria (proteinuria 
1+). Complete response was observed in 1 patient (patient 
16), and partial response was observed in 5 patients (patient 
3, 5, 6, 11 and 13). Three of nine patients with lupus nephritis 
and two of four patients with FSGS showed partial response. 
One patient was eventually expired (patient 7). 
4. TPE procedure and complications
The 16 patients underwent a total of 104 sessions. The 
average frequency of TPE per each case was 5.5±3.8 ses­
sions, and the procedures were carried out using a central 
venous catheter. The type of vascular access was chosen 
based on the patient’s vascular anatomy and the most com­
mon site was the subclavian vein (8 cases), followed by the 
internal jugular vein (5 cases). The replacement fluids were 
4% albumin (9 cases, 47%) or FFP (5 cases, 26%) according 
to the patients’ general condition. Four compli cations 
were reported for the 104 TPE sessions (hypovo lemia, 
anemia, hypocalcemia, and thrombocytopenia) (Table 7). 
Discussion 
Although TPE has been increasingly used as a first­line 
therapy in the last few decades, there is a lack of research 
about TPE in pediatric kidney diseases. Therefore, the aim 
of this study was to analyze the therapeutic effect of TPE 
in pediatric kidney diseases11,12). 
In 1980, plasmapheresis was introduced in Korea, and 
the first procedure was performed in Severance Hospital 
in a patient with membranous proliferative glomerulo­
nephritis in 1981. TPE non­selectively removes pathogenic 
substances or replaces a deficient factor, as in systemic 
thrombotic microangiopathy3). The ASFA Special Issue, 
7th edition, published in 2016 classifies disorders into four 
categories. Category I is accepted as first­line therapy, and 
category II is accepted as supportive or adjunctive therapy. 
However, category III is not established, and category IV is 
ineffective or harmful6). There are few published reports 
Table 7. TPE Procedure and Complications
Patient Diagnosis Number of sessions Replacement solution Vascular access Complication
1 Lupus nephritis   3 4% albumin Subclavian vein -
2 Lupus nephritis   3 4% albumin Subclavian vein -
3 Lupus nephritis   5 NA NA -
4 Lupus nephritis   5 NA Internal J. V. Hypovolemia
5 Lupus nephritis   3 4% albumin Internal J. V. -
6 Lupus nephritis   3 NA NA -
7 Lupus nephritis   3 4% albumin NA -
8 Lupus nephritis   6 NA NA -
9-1 Lupus nephritis 10 FFP Internal J. V. -
9-2   5 4% albumin Subclavian vein -
10-1 FSGS 15 4% albumin Subclavian vein Anemia
10-2   5 FFP Subclavian vein -
11-1 FSGS 14 4% albumin Subclavian vein -
11-2   3 FFP Subclavian vein Hypocalcemia
12 FSGS   9 4% albumin Internal J. V. -
13 FSGS   3 FFP Femoral vein -
14 Denys-Drash syndrome   2 4% albumin Internal J. V. -
15 Microscopic polyarteritis   4 NA NA -
16 Atypical HUS   3 FFP Subclavian vein Thrombocytopenia
Abbreviations: FFP, fresh frozen plasma; FSGS, focal segmental glomerulosclerosis; HUS, hemolytic-uremic syndrome; Internal J. V., internal jugular vein; NA, 
not available.
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about TPE conducted in pediatric patients, thus, the indi­
cations for TPE in children are based on those in adults.
Song et al. showed that the most common indications of 
TPE in the nationwide survey on Korea were myasthenia 
gravis (15.3%), followed by thrombotic thrombocytopenic 
purpura (TTP) (14.5%), and HUS (9.7%)13). Volder et al. 
showed that TPE indications in pediatric and adolescent 
patients from the World Apheresis registry data were neu­
rological diseases (33%) and renal diseases (17%). Paglia­
longa et al. reported that the indications of TPE in European 
pediatric nephrology units were FSGS (16.4%) and HUS/
TTP (17.9%)8,14). In addition, Reddy et al. reported that the 
etiologies for TPE were aHUS (75%), anti­glomerular base­
ment membrane disease (12.5%), lupus nephritis (6.25%), 
and microscopic polyangiitis (6.25%) (Table 8)15). In our 
single­center study, the indications of TPE in pediatric 
patients with kidney diseases were lupus nephritis (52.6%), 
FSGS (31.6%), and HUS/TTP (15.8%). 
TPE in lupus nephritis is classified as Category IV accor­
ding to the ASFA. Lewis et al. showed that TPE in combi­
nation with prednisolone and cyclophosphamide is not as 
effective for the treatment of lupus nephritis as compared 
with prednisolone and cyclophosphamide alone6). On the 
contrary, Li et al. reported that lupus nephritis patients with 
thrombotic microangiopathy who underwent TPE had a 
significantly higher rate of remission than those who did 
not undergo TPE16,17). In this study, TPE in a lupus nephritis 
patient with thrombotic TTP (patient 5) had a clinical 
effect. Currently, the patient has no proteinuria and is re­
gularly followed up at the outpatient clinic. Among the 
remaining lupus nephritis patients who underwent TPE, 
no children have progressed to ESRD, 3 patients (patient 3, 
patient 5, and patient 6) are undergoing outpatient obser­
vation and 3 patients (patient 1, patient 2, and patient 8) 
failed to attend follow up visits in our clinic. In addition, 1 
patient (patient 4) moved to another hospital after improve­
ment, and 1 patient (patient 7) died due to exacerbation of 
pneumonia. While TPE for lupus nephritis is classified as 
Category IV according to the ASFA, the results of the pre­
sent study show that TPE has some effect on lupus nephritis.
In a review article by Ponticelli et al., 70% of recurrent 
FSGS children who underwent TPE presented complete or 
partial remission, and according to Straatmann et al., early 
TPE was 100% effective in patients with recurrent FSGS18, 
19). In this study, the patient (patient 11) with recurrent FSGS 
who underwent TPE 6 days after kidney transplantation 
presented complete remission. However, the patient (patient 
10) with recurrent FSGS who underwent TPE 4 months 
after kidney transplantation progressed to ESRD and was 
on hemodialysis. Therefore, early TPE in patients with re­
current FSGS may be important to improve the prognosis.
The ASFA guideline classifies TTP for ABO incompatible 
Table 8. Comparisons of Our Study with Previous Studies Regarding Therapeutic Effects of TPE
Paglialonga, et al8) Reddy, et al15) Ours
Publication year 2015 (Europe) 2015 (India) - (Korea)
Study period 2012 2009-2013 1994-2016
No. of Patients 67 (M 29/F 38) 16 (M 10/F 6) 16 (M 2/F 14)
Age ≤18 yrs 5-18 yrs ≤18 yrs
Etiologies HUS/TTP 17.9% aHUS 75% Lupus nephritis 56%
FSGS 16.4% anti-GBM 12.5% FSGS 25%
Desensitization of rTx 13.4% Lupus nephritis 6.25% Desensitization of rTx 6.3%
MPA 6.25%
No. of procedurs 6 11 5.2
Replacement fluid Albumin (46.2%) NA Albumin (50%)
Plasma (31.3%) FFP (25%)
Albumin+plasma (11.9%)
Complications Total 6.9 % Cath.related inf. 18.8% Total 3.8 %
Allergic reaction 12.5%
Abbreviations: aHUS, atypical hemolytic uremic syndrome; anti-GBM, anti-glomerular basement membrane disease; F, female; FFP, fresh frozen plasma; M, 
male; MPA, microscopic polyangiitis; No., number; rTx, renal transplantation; FSGS, focal segmental glomerulosclerosis; ;TTP, thrombotic thrombocytopenic 
purpura; NA, not available.  
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renal transplantation as Category I. In this study, TPE was 
performed as first­line treatment for TTP (patient 9 and 
patient 13) and ABO incompatible renal transplantation 
(patient 14) and resulted in BUN reduction, creatinine re­
duction, and clinical effectiveness. 
Paglialonga et al. showed that TPE complications in pe­
diatric nephrology units occurred in 51 of 738 sessions (6.9 
%). According to Volker et al., complications were reported 
in 4 out of 50 sessions (8%), and in this study, complications 
were found in 4 out of 104 sessions (3.8%)8,20). None of the 
complications led to death, and all were resolved. Although 
TPE is a safe and effective therapeutic tool, Pamela et al. 
reported that among patients hospitalized with ASFA Ca­
tegory I or II disease, only 13.4% and 9.3% underwent TPE, 
respectively21). In this study, when TPE was performed in 
patients with diseases corresponding to ASFA Category I 
and II, TPE was clinically effective in 5 (patient 9, 11, 13, 14, 
and 16) of 6 patients, and only 1 patient (patient 15) was on 
hemodialysis due to progressed ESRD. Therefore, it is 
thought that TPE will be helpful as therapeutic modality 
in children with kidney disease.
When TPE is performed, albumin and FFP are most 
commonly used as replacement fluid. Regarding the ad­
vantages and disadvantages of each fluid, albumin is rela­
tively expensive but has a lower risk of transfusion­trans­
mitted infection. FFP maintains the activity of all blood 
coagulation factors but has a high risk of viral transmission 
and more frequent adverse reactions such as allergic reac­
tions22,23). Albumin is used more than plasma due to the 
lower risk of allergic reactions and transmission of viral 
infections by plasma24). In this study, albumin (47%) was 
used more frequently than FFP (26%). Depending on the 
underlying disease and the laboratory findings, the selec­
tion of appropriate replacement fluid is important.
Carter et al. reported that catheter­related complications 
such as catheter­related thrombosis and infection were 
common when TPE was used in pediatric patients3). Ca­
theter­related complications should be considered when 
performing TPE in children, but these were not reported 
in this study. Additional considerations for the improve­
ment of TPE outcomes in children include safe sedation in 
non­cooperative patients and vascular access methods.
Overall, the present study has some limitations including 
its retrospective design and the inclusion of a small number 
of patients. As TPE was used in combination with immu­
nosuppressive therapy, the therapeutic effect of TPE alone 
was not evaluated in this study. In addition, insurance­
related factors may have affected the results of our study. 
For example, the category proposed by ASFA for certain 
diseases such as FSGS was changed from Category III in 
2007 to Category I in 2010. In Korea, we decided to apply 
insurance based on the ASFA guideline, so patient 12 in 
this study who underwent TPE in 2008 did not receive 
insurance benefits25,26). If insurance was more applicable to 
TPE, it will be helpful in treating children with many 
kidney diseases.
In conclusion, TPE may be a safe and effective treatment 
in pediatric kidney disease patients and can be indicated 
for the treatment various kidney diseases. Further studies 
are necessary to investigate the overall results in other 
hospitals and institutions in Korea. 
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